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Differing effects of acid versus neutral phosphate therapy in
idiopathic hypercalciuria. Studies were performed on 12 patients
with idiopathic hypercalciuria to evaluate the hypothesis that the
acid load accompanying potassium acid phosphate would ad-
versely affect renal calcium reabsorption and citrate excretion
compared to the neutral form of the phosphate salt. During acute
clearance studies, neutral phosphate (NP) led to a fall in FE0a
(2.2 0.6% to 0.8 0.1%, P < 0.02) and no change in titratable
acidity (TA) or net acid excretion (NAE). Acid phosphate (AP)
did not reduce FEE. acutely, and led to a rise in TA (22 4 to 62
6pEq/min, P < 0.02) and NAE (46 6 to 89 7 Eq/min, P
< 0.02). During chronic administration, AP resulted in higher
urinary calcium excretion in both absorptive (187 29 vs. 141
18 mg/day, P < 0.02) and renal hypercalciuric patients (233 24
vs. 173 190.02 mg/day, P < 0.02). Also, TA and NAE were
higher following AP, whereas citrate excretion was lower (375.4
64.6 vs. 633.4 28.8 mg/day, P < 0.01). These data suggest
that the reported ineffectiveness of AP in the therapy of nephroli-
thiasis may be related to the deleterious effects of the acid load
on calcium and citrate metabolism.
Effets différents du traitement de l'hypercalciurie par les formes
acide ou neutre du phosphate. Douze malades atteints
d'hypercalciurie idiopathique ont été étudiés pour évaluer
I'hypothèse scion laquelle la charge acide incluse dans le phos-
phate acide de potassium pourrait défavorablement influencer Ia
reabsorption rénale de calcium et l'excrétion urinaire de citrate
par comparaison avec la forme neutre du phosphate, Au cours
d'études aiguës, le phosphate neutre (NP) a déterminé une chute
de FE8 (2,2 0,6% a 0,8 0,1%; P < 0,02) et pas de modifica-
tion de l'acidité titrable (TA) ou de l'excrétion nette d'acide
(NAE). Le phosphate acide ne diminue pas FEca et determine
une augmentation de TA (22 4 a 62 6 iEq/min; P < 0,02) et
de NAB (46 6 a 89 7 EqImin; P < 0,02). Au cours de
l'administration chronique, Ic phosphate acide determine une cx-
crétion urinaire de Ca plus importante aussi bien chez les ma-
lades atteints d'hypercalciurie par hyperabsorption (187 29 vs.
141 18 mg/jour; P < 0,02) que chez ceux ayant des hyper-
calciuries rénales (233 24 vs. 173 190,02 mg/jour; P < 0,02).
Dc même TA et NAE étaient plus élevées aprés i'administration
de phosphate acide alors que l'excrétion de citrate était diminuCe
(375,4 64,6 vs. 633,4 28,8 mg/jour P < 0,01). Ces observa-
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tions suggèrent que l'inefficacité du phosphate acide dans Ic
traitement de Ia lithiase rénale peut être liée aux effets nuisibles
de la charge acide sur les métabolismes du citrate et du calcium.
Orthophosphates have long been used to treat pa-
tients with idiopathic calcium calculi [1—7]. The ra-
tionale for this mode of therapy is based on the
known hypocalciuric effects of phosphate [2-5] and
the associated increase in excretion of inorganic
pyrophosphates [1, 4], one of the major urine inhib-
itors of calcium crystal formation and aggregation
[1, 3, 4].
Despite these theoretical considerations, treat-
ment of calcium nephrolithiasis with phosphate has
produced equivocal clinical results [1—8]. Indeed,
one recent controlled study failed to demonstrate
any superiority of phosphate over diet treatment or
placebo control [8]. One factor previously not con-
sidered as a cause of treatment failure is the hydro-
gen ion content of the form of phosphate used. In-
creased calcium excretion has been repeatedly ob-
served with chronic ingestion of acid-ash or
ketogenic diets [9] or administration of calcium
chloride [9], ammonium salts [9—11], or methionine
[11]. It is therefore possible that the hydrogen ion
contained in acid phosphate could similarly in-
crease urine calcium excretion, offsetting any hypo-
calciuric effect exerted on the kidney by the phos-
phate moiety [6, 9, 12]. In addition, it is possible
that the hydrogen ions in the acid salt could produce
a mild form of metabolic acidosis and reduce urine
excretion of citrate—a major urinary ligand for cal-
cium [13, 14]. To test these two hypotheses, we per-
formed the following randomized studies in patients
with hypercalciuria to compare the acute and
chronic effects of acid phosphate and neutral phos-
phate on the excretion of components of acid-base
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metabolism and stone-forming salts. The results
suggest that acid phosphate does not reduce urine
calcium excretion to a greater degree than that seen
following dietary calcium restriction. The data also
indicate that acid phosphate administration is asso-
ciated with increased net acid excretion and re-
duced citrate excretion.
Methods
Patients with recurrent calcium-containing stones
were screened as outpatients in the Kidney Stone
Evaluation Center at the Hospital of the University
of Pennsylvania. Patients studied had at least two
stone episodes in the past (stone passage or radio-
logic appearance of at least two stones). The follow-
ing protocol was used: Two 24-hour urine samples
were collected on days 6 and 7 of a diet regimen
containing 400 mg of calcium per day (low-Ca diet).
On day 8, a 2-hour morning urine specimen was ob-
tained after a 12-hour overnight fast to determine
the calcium-to-creatinine ratio. A fasting-blood
sample was drawn to determine the serum calcium,
phosphate, uric acid, creatinine, and electrolyte
concentrations. The low-Ca diet was continued for
another 7 days, but intake of calcium was raised to
900 mg/day with the addition of oral calcium car-
bonate (1200 mg) in two divided doses. Similar 24-
hour urine and fasting blood specimens were ob-
tained for identical chemical determinations. A
short ammonium-chloride-loading test was per-
formed as described by Wrong and Davies [15].
Hypercalciuria was considered present if calcium
excretion was in excess of 265 mg/day while on the
900-mg calcium diet, regardless of sex or weight.
All patients had a normal plasma calcium concen-
tration and ability to reduce urine pH 5.3 after
ammonium chloride. Patients were categorized as
having renal hypercalciuria (RH) if calcium excre-
tion continued to exceed 265 mg/day after reduction
of dietary calcium to 400 mg/day. This method of
classification was independently validated with a
clear separation between patients with RH and pa-
tients with absorptive hypercalciuria (AH), by using
the 2-hour urine calcium-to-creatinine ratio crite-
rion proposed by Pak et al [16]. The ratio in RH
(0.15 [sEMi 0.02; N = 15) was significantly (P <
0.02) greater than that in AH (0.10 0.01; N = 28).
Primary hyperparathyroidism was ruled out by
demonstration of normal serum calcium level and
normal serum immunoreactive PTH level in each
patient (< 9 .t1JEq/m1).
Studies were performed on 12 patients with hy-
percalciuria (6 RH and 6 AH) aged between 22 and
51 years. Eight were males, and 4 were females. All
had a serum creatinine concentration of  0.016
mg/ml and sterile urine. None was on any medica-
tions known to influence acid-base metabolism or
calcium, phosphate, or sodium excretion for at least
2 weeks prior to studies. The protocols were ap-
proved by the Human Study Committee of the Uni-
versity of Pennsylvania, and each patient gave in-
formed consent prior to entry into the study. All
clearance studies were performed in the Clinical
Research Center of the Hospital of the University
of Pennsylvania.
Acute effects of acid and neutral phosphate (N =
7). After a 12-hour overnight fast, patients under-
went clearance studies during sustained water di-
uresis according to methods previously reported by
this laboratory [17]. When steady state was
reached, urine was obtained under oil with a simul-
taneous midpoint blood sample to determine plasma
pH and to calculate the clearances of PAH, inulin,
sodium, calcium, phosphate, and potassium. Ortho-
phosphate in the dosage of 1 g of elemental phos-
phorus was then administered orally. The effects on
urine acid-base and electrolyte excretion were eva!-
uated over the ensuing 3 hours after phosphate ad-
ministration with similar clearance techniques. One
gram of elemental phosphorus as acid phosphate
(K-PHOS®, Beach Pharmaceuticals) contains 9
mEq of potassium and 23 mEq of sodium as the
monobasic salts. One gram of elemental phos-
phorus as neutral phosphate (Neutra-Phos, Willen
Pharmaceuticals) contains 28 mEq of sodium and 28
mEq of potassium, with both monobasic and dibas-
ic forms of phosphate present (dibasic to monobasic
ratio, 3:1; pH, 7.3). The difference in the amount of
fixed base (56 — 32 = 24 mEq) represents the hydro-
gen ion load per gram of elemental phosphorus that
must be buffered and excreted when using the acid
phosphate preparation. Both the acid and neutral
forms of phosphate were evaluated in each patient
by two identical studies separated by 4 to 6 weeks
and in randomized sequence.
Chronic effects of acid and neutral phosphate
(N = 10). The day after the acute studies, the chron-
ic phase began with oral administration, in three di-
vided doses, of either acid or neutral phosphate fol-
lowing meals. The dose of phosphate was equiva-
lent to 2 g of elemental phosphorus per day except
in two patients who developed diarrhea and took
only 1.5 g of phosphorus per day during both phos-
phate periods. Patients were instructed to maintain
their usual diet throughout the two treatment peri-
ods. Diet history revealed an intake of calcium be-
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tween 700 mg and 1,000 mg/day, and there was no
substantial difference in intake of calories, purines,
protein, sodium, phosphate, and calcium between
the two treatment periods. On the last 2 days of the
7 to 10 days of treatment, 24-hour urine samples
were collected under oil for determination of creati-
nine, sodium, potassium, calcium, phosphate, pH,
titratable acid, and ammonium.
Plasma and urine concentrations of creatinine,
PAH, inulin, uric acid, sodium, and potassium were
measured by methods previously described [17].
Serum and urine concentrations of calcium were
measured by titration with EDTA as previously re-
ported methods [18]. Serum and urine concentra-
tions of phosphate and urine citrate and pH were
analyzed by methods previously described [18]. Ti-
tratable acidity was determined by potentiometric
titration of original urine pH to the pH of the plasma
with a Beckman pH electrode. Ammonium was
measured by an ammonium electrode. Serum PTH
levels were measured in the laboratory of Dr. E.
Slatopolsky.
Clearance (C) of a substance x was calculated by
the equation
Cx =
where U, and P, refer to concentration of x in urine
and plasma, respectively, and where V refers to
urine flow rate in milliliters per mm. Fractional ex-
cretion of x is defined as the ratio of the clearance of
x to that of inulin. Statistical analysis was per-
formed with paired and nonpaired Student's t tests
(two-sided) wherever appropriate. A P value of <
0.05 was considered significant. All data are report-
ed as means SEM.
Results
Acute effects of orthophosphate administration
on plasma and clearance data (Table I and Fig. I).
Pretreatment values refer to the data obtained for
30
25
20
15
10
5
0
NS P<0.01II I
A N A N
p p P
the three to four clearance periods of 20 mm each
immediately prior to administration of phosphate.
Posttreatment values refer to the data obtained for
the three clearance periods of 20 mm each during
which maximal hypocalciuric effects were obtained.
Table 1. Acute effects of orthophosphates on plasma and clearance dataa
Pca
mEqiliter
P,4
ingidi
CPAH
mi/mm
Clfljfl
mi/mm
Pre Post Pre Post Pre Post Pre Post
Acid P04 (N = 7) 4.86 4.71 3.0 4•5h 464 465 107 107
Neutral P04 (N = 7) 4.72 4.66 3.1 43b 494 47S 109 104
P value NS NS NS NS NS NS NS NS
ayalues are means SEM. Pre and post refer to values before and after phosphate administration.
b Indicates statistical significance compared to pre-treatment values (P < 0.05). NS is not significant.
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Fig. 1. Acute effects of orthophosphate on urinary' hydrogen ion
excretion in hypercalciuria. AP denotes acid P04, and NP de-
notes neutral P04. Asterisks indicate significant difference com-
pared to pretreatment. P values refer to differences between AP
and NP. Values are means SEM.
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The pretreatment plasma calcium and phosphate
concentrations were similar between the acid-phos-
phate-treated and neutral-phosphate-treated groups
(Table 1). After drug administration, plasma cal-
cium concentration remained similar between the
two groups. There was a significant increase in
plasma phosphate concentration after administra-
tion of both forms of phosphate, but the increment
was similar and the final phosphate concentrations
were comparable (0.045 0.005 vs. 0.043 0.002
mg/mi). Effective renal plasma flow, as estimated
by the clearance of PAll was similar both before
and after drug administration, as was GFR (Table
1).
The acute effects of phosphate on hydrogen ion
excretion are depicted in Fig. 1. Titratable acid was
similar prior to treatment but rose after acid phos-
phate administration to 62 6 Eq/min (P < 0.02),
a level significantly greater than that after neutral
phosphate administration (25 7 Eq/min, P <
0.005). Ammonium excretion was also similar be-
fore treatment, but it was significantly greater after
acid phosphate than it was after neutral phosphate(29 4 vs. 16 3 Eq/min, P < 0.01). Urine pH
(not shown on Fig. 1) was similar before treatment
(6.17 0.10 vs. 6.26 0.18). It was slightly but
significantly lower after acid phosphate (5.98 0.09
vs. 6.53 0.16, P < 0.03). Net acid excretion, com-
parable before treatment, was significantly in-
creased (P < 0.02) after acid phosphate than it was
after neutral phosphate (89 7 vs. 42 6 p.Eq/min;
P < 0.001). Venous pH, Pco2, and bicarbonate con-
centrations were determined prior to and following
acid phosphate and neutral phosphate administra-
tion in 5 patients. There were no significant dif-
ferences in any of these values either before or after
treatment or between the two forms of phosphate.
The fractional excretion of sodium and phosphate
was comparable between the two treatment groups
before phosphate administration. The fractional ex-
cretion of phosphate rose significantly (P < 0.01) to
42.3 4.1% (acid phosphate) and to 33.8 4.8%
(neutral phosphate). These values were not signifi-
cantly different from each other. Calcium excretion
fell from 12.3 2.9 to 8.39 1.8 sEq/min (P =
0.06) following acid phosphate and from 10.7 3.1
to 4.67 1.35 tEq/min (P < 0.005) following neu-
tral phosphate. The fall after neutral phosphate
(6.03 1.91 tEq/min) was significantly greater than
that seen following acid phosphate (3.9 14 Eq/
mm, P < 0.005). A greater fall in ultrafilterable cal-
cium concentration after neutral phosphate than
that after acid phosphate could have caused the ob-
served effects of excretion of calcium. Because to-
tal serum calcium and phosphate concentrations
(Table 1), as well as venous pH (7.34 0.01 after
acid phosphate, N = 5; 7.36 0.01 after neutral
phosphate, N = 5, NS), however, were not dif-
ferent following acid compared to neutral phos-
phate, it is likely that ultrafilterable calcium was
similar in the two groups.
Chronic effects of phosphate administration are
summarized in Table 2. Urine volumes were com-
parable between acid and neutral phosphate treat-
ment, as were 24-hour urine creatinine, phosphate,
and sodium excretions. The slightly greater abso-
lute values for sodium in the neutral phosphate
treatment group probably reflected the greater so-
dium content of the neutral phosphate capsules (57
vs. 45 mEq/day). Potassium excretion was signifi-
cantly lower during acid phosphate therapy than it
was during neutral phosphate therapy (65 7 vs.
98 11 mEq/day, P < 0.02), reflecting the sub-
stitution of the hydrogen ion by 28 mEq of potas-
sium contained in the daily dose of neutral phos-
phate. Uric acid excretion (not shown in Table 2)
was comparable between acid and neutral phos-
phate treatment (576 69 vs. 621 75 mg/day).
Excretions of titratable acid (69.3 3 vs. 38.7
6.8 mEq/day, P <0.005), ammonium (36.1 3.1 vs.
18.9 3.0 mEq/day, P < 0.005), and net acid (105
7 vs. 56 8 mEq/day, P < 0.001) were greater dur-
ing acid than they were during neutral phosphate
treatment. Twenty-four-hour calcium excretion was
also higher during acid than it was during neutral
administration (209 19 vs. 157 15 mg/day, P <
Table 2. Chronic eifects of orthophosphates on urine chemistriesa
Dose Creat. Na P04 K Titratable acid NH4 Net acid Ca Citrate
mi/day glday mEq/day g/day mEqiday mEqiday mEq/day mEq/day mg/day mg/day
Acid P04 (N 10) 2036 1.6 198 2.3 65 69.3 36.1 105 209 375.4
NeutralPO4(N= 10) 2016 1.6 220 2.2 98 38.7 18.9 56 157 633.4
P value NS NS NS NS <0.02 <0.005 <0.005 <0.001 <0.02 <0.01
a Values are means SEM. P values refer to statistical comparison between acid and neutral phosphate therapy.
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0.02). Urine citrate excretion was significantly re-
duced with acid compared to neutral phosphate
treatment (375.4 64.6 vs. 633.4 28.8 mg/day,
P < 0.01).
The relative hypocalciuric potencies of a low-cal-
cium diet, acid, and neutral phosphate therapy were
compared in 5 patients with AH, and separately in 5
patients with RH (Table 3). Compared to the 900-
mg calcium diet, the low-calcium diet reduced uri-
nary calcium excretion in both AH (328 20 to
205 15 mg/day, P < 0.001) and RH (337 21 to
274 18 mg/day, P < 0.05). Acid phosphate treat-
ment, however, did not further reduce calcium ex-
cretion beyond the effects of a low-calcium diet in
either AH or RH. In contrast, neutral phosphate
during the normal calcium diet treatment signifi-
cantly lowered the calcium excretion in AH when
compared to that achieved either by a low-calcium
diet (141 18 vs. 205 75 mg/day, P < 0.02) or by
acid phosphate (141 18 vs. 187 29 mg/day, P <
0.05) alone during normal calcium intake. A similar-
ly greater hypocalciuric effect of neutral phosphate
treatment was observed in the 5 patients with RH
when compared to either a low-calcium diet (173
19 vs. 274 18 mg/day, P < 0.02) or acid phosphate
therapy (173 19 vs. 233 24mg/day, P <0.05).
Discussion
Although early clinical trials claimed good results
in the treatment of idiopathic calcium stone disease
with phosphate [2, 3, 5, 7], one recent double-blind
study with diet and placebo as controls could not
demonstrate a similar benefit from phosphate thera-
py [8]. Among the possible reasons for these con-
flicting results are: insufficient dosages of phosphate
[5, 19], variable follow-up periods, or some hitherto
unappreciated factors associated with phosphate
therapy that favor stone formation and/or growth.
One factor previously not emphasized or investi-
gated is the form of phosphate administered, with
specific reference to the effects of phosphate thera-
py on acid-base balance.
Findings from our studies support the thesis that
acid and neutral phosphates do produce different ef-
fects on the excretion of solutes thought to be im-
portant in the genesis of urinary stones. First, neu-
tral phosphate is hypocalciuric, whereas acid phos-
phate is not (Table 3). Second, urine citrate
excretion is significantly reduced by acid phosphate
(Table 2).
Acute phosphate administration is known to en-
hance renal tubular calcium reabsorption independ-
ently of PTH [20, 21] and changes in ultrafiltrable
calcium [20]. A hypocalciuric effect with chronic
administration has also been observed [2—5, 7]. In-
creased calcium excretion, however, often accom-
panies increased acid ingestion and/or production,
as in the consumption of a high-protein diet [9, 20],
a ketogenic diet [9], or in the ingesting of calcium
chloride or ammonium salts [9-11]. We reasoned
that if the hydrogen ion moiety of acid phosphate
increases calcium excretion similar to the other
nonphosphate containing acid salts, the hypocal-
ciuric effect of the phosphate moiety per se could be
nullified. Our results are compatible with this for-
mulation. Moreover, the differences we observed in
the renal excretion of calcium and components of
acid base metabolism could not be attributed to dif-
ferences in plasma calcium and phosphate, clear-
ances of inulin or PAH (Table 1), or excretion of
sodium or phosphate, because all these parameters
were comparable between the two forms of phos-
phate treatment both before and after acute admin-
istration.
Results from our chronic phosphate studies con-
firm and extend the acute findings. At comparable
daily excretions of sodium and phosphate (Table 2),
calcium excretion was significantly greater during
acid phosphate treatment (Tables 2 and 3), associat-
ed with an increase in titratable acid, ammonium,
and net acid excretion (Table 2). These acid-base
data provide a physiologic explanation for the clini-
cal observation of a lack of effect of acid phosphate
administration on calcium excretion in both normo-
calciuric subjects [6, 9] and hypercalciuric stone pa-
tients [12, 23].
In both the renal and absorptive subgroups of
idiopathic hypercalciuria, both acid and neutral
phosphate treatment reduced calcium excretion
Table 3. Effects of treatment with low-calcium (400 mg) diet, acid
phosphate and neutral phosphate on 24-hour urine calcium
excretion in absorptive (AH) and renal hypercalciuna (RH)
Calcium excretion, mg/day
AH RH
(N=5) (N=5)
900-mg Ca diet 328 20
p < 000th
337 21
p < 005b
400-mg Ca diet 205 15
NS
274 18
NS
Acid P04 187 29
p < 005b
233 24
p < 005b
Neutral P04 141 18 173 19c
a Values are means SEM.
bp values denote significant differences between values above
and below.
P < 0.02, compared to low-calcium diet.
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when compared to the excretion measured while on
a 900-mg calcium diet (Table 3). But acid phosphate
failed to lower daily calcium excretion beyond that
achieved by diet calcium restriction alone in either
absorptive hypercalciurics or in renal hyper-
calciurics. In contrast, further reduction in calcium
excretion beyond that achieved by a low-calcium
diet was possible with neutral phosphate therapy
(Table 3). These clinical data are consistent with the
recent clinical observation that acid phosphate was
no more efficacious than dietary calcium restriction
in producing remission of stone disease [8].
Neutral phosphate uniformly produces a greater
reduction in calcium excretion than do equivalent
doses of acid phosphate in both AH and RH (Table
3). These findings therefore support the notion that
the variable hypocalciuric response during phos-
phate therapy reported in the literature [3, 5—8] is
due to the hydrogen ion contained in the acid phos-
phate, rather than to the slight difference in dos-
ages. Furthermore, our data are consistent with the
recent finding that, with respect to calcium oxalate,
the calculated relative urinary supersaturation was
decreased by neutral but not by acid phosphate
[23].
Urinary citrate excretion, an important calcium
ligand in the urine, consistently falls during intra-
cellular acidosis [24] and/or metabolic acidosis due
to a variety of etiologies: uremia, ketoacidosis, am-
monium chloride or hydrochloric acid administra-
tion [25, 26], and distal renal tubular acidosis [26].
In addition, recent studies suggest that reduced uri-
nary citrate excretion may characterize some pa-
tients with hypercalciuria and recurrent nephroli-
thiasis [27]. At a physiologic plasma pH of 7.4 and
with a pK' of 6.8 for dibasic/monobasic phosphate,
we estimate that 48 mEq of hydrogen ion could be
generated from the 64 mmoles of acid phosphate in-
gested daily, an acid load sufficient to decrease cit-
rate excretion. Our studies indeed indicate that
therapy with acid phosphate was accompanied by
an increased net acid excretion (by approximately
50 mEq/day, Table 2) and decreased urinary citrate
excretion (Table 2).
It should be noted that phosphate therapy has
been shown to increase the excretion of inorganic
pyrophosphate [1, 3, 4], a putative inhibitor of cal-
cium phosphate crystallization. Our data do not ad-
dress the possible differences in excretion of this
compound during administration of the acid and
neutral form of phosphate. Also, our data demon-
strate no difference in urinary uric acid or sodium
excretion between the two forms of phosphate.
These data argue against significant alteration in pu-
rine excretion as a cause of the variable clinical re-
sponse reported with oral phosphate therapy.
Our acute and chronic data support the thesis
that, in contrast to neutral phosphate, acid phos-
phate does not produce comparable beneficial ef-
fects on urinary excretion of certain stone-forming
salts or on the excretion of calcium ligands in the
urine. The data suggest therefore that the neutral
salt would be the preferred form of phosphate for
treatment of calcium oxalate calculi when clinically
indicated.
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